CD274 and melanoma: have generated in vivo models with one or two concurrent sites of metastases by injecting subcutaneously, intrahepatically or intrasplenically melanoma (B16F10), colon adenocarcinoma (MC38) and pancreatic ducal adenocarcinoma (KPC2) cell lines, to assess response to anti-PD-L1 treatment and changes in the tumor immune microenvironment (59).